GHA
CPRX

GW Henssler & Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

GW Henssler & Associates’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,481
Closed -$206K – 191
2025
Q1 		$206K Buy
+8,481
New +$191K 0.01% 167

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GW Henssler & Associates's CPRX Position: Q2 2025 in Review

GW Henssler & Associates sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 8,481 shares — an estimated $206K sold.

GW Henssler & Associates first reported a position in CPRX in Q1 2025 and held it in 1 quarter. The position peaked at $206K in Q1 2025. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • GW Henssler & Associates reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • GW Henssler & Associates sold 8,481 Catalyst Pharmaceutical shares in Q2 2025, an estimated $206K.
  • GW Henssler & Associates first reported a position in Catalyst Pharmaceutical in Q1 2025 and held it in 1 quarter.
  • GW Henssler & Associates's Catalyst Pharmaceutical position peaked at $206K in Q1 2025.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on GW Henssler & Associates's 13F filing for Q2 2025, filed 25 Jul 2025.